Assessing renal structural alterations and outcomes
This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.
1. A method for treating a mammal having an increased risk of acute decompensated heart failure, wherein said method comprises:
(a) determining that said mammal has an elevated level of urinary NT-CNP-53,
(b) monitoring said mammal for the presence of a risk factor for said acute decompensated heart failure, and
(c) administering an ACE inhibitor, an angiotensin receptor blocker, an aldosterone antagonist, a statin, a native natriuretic peptide, or a designer natriuretic peptide to said mammal.
2. The method of claim 1 , wherein said mammal is a human.
3. The method of claim 1 , wherein said elevated level is greater than 36,000 pg of NT-CNP-53/day.
4. The method of claim 1 , wherein said elevated level is greater than 42,000 pg of NT-CNP-53/day.
5. The method of claim 1 , wherein said risk factor is selected from the group consisting of an age factor, hypertension, an elevated serum creatinine level, proteinuria, an elevated body mass index, an elevated cholesterol level, a smoking habit, and diabetes.
6. The method of claim 1 , wherein said method comprises administering said angiotensin receptor blocker to said mammal.